Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas.
In all 63 patients were treated monthly with a combination of mitomycin, doxorubicin, and cisplatin, and 27 (43%) experienced objective regression of their advanced sarcomas during a 3-month trial. The observed regression rate is numerically higher than any previously observed at our institution.